文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

362例接种或未接种疫苗的新冠病毒奥密克戎变异株感染患者临床特征分析

[Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论奥密克戎传染性极强但症状轻;疫苗尤其加强针对防重症和改善预后仍然有效。

前瞻性单中心观察研究纳入2022年1月8日至2月2日天津定点医院连续收治的362例奥密克戎感染患者,其中加强针组136例(37.57%)、常规疫苗组190例(52.49%)、未接种组36例(9.94%)。结果发现加强针组和常规疫苗组IgG抗体滴度、轻型比例均高于未接种组,且加强针组又高于常规疫苗组。未接种组重症比例、核酸转阴时间、病程及重症监护病房(ICU)入住比例均高于常规疫苗组和加强针组,差异均有统计学意义(均 P < 0.05)。作者认为奥密克戎传染性极强、聚集性发病但症状轻,疫苗尤其加强针对防重症、改善预后仍然有效。

要点

  • 加强针组和常规疫苗组IgG抗体滴度均高于未接种组,且加强针组高于常规疫苗组,差异均有统计学意义(均 P < 0.05)。
  • 加强针组、常规疫苗组、未接种组轻型比例分别为66.91%(91/136)、48.94%(93/190)、27.28%(10/36),差异有统计学意义(均 P < 0.05)。
  • 未接种组重症比例5.56%(2/36)高于常规疫苗组0.53%(1/190)和加强针组0(1/136),差异有统计学意义(P < 0.05)。
  • 未接种组核酸转阴时间、病程均为15(11,16)天,长于常规疫苗组、加强针组的12(10,15)天和13(11,15)天,差异有统计学意义(均 P < 0.05)。
  • 未接种组ICU入住比例16.67%(6/36)高于常规疫苗组2.63%(5/190)和加强针组0.74%(1/136),差异有统计学意义(P < 0.05)。

适用人群与场景

  • 2022年1月8日至2月2日由天津市第三中心医院天津新冠救治医疗队负责的新冠定点医院连续收治的奥密克戎变异株感染患者362例。
  • 按疫苗接种状态分为加强针组136例(37.57%)、常规疫苗组190例(52.49%)、未接种组36例(9.94%)。

处置流程与药物剂量

  • 患者均接受医学隔离,主要治疗措施包括中药辨证(中药或补剂)265例(73.20%)、俯卧位治疗188例(51.93%)、低分子肝素抗凝106例(29.28%)、胸腺法新免疫调节治疗21例(5.80%)、抗菌药物20例(5.52%)、经鼻高流量氧疗12例(3.31%)、糖皮质激素5例(1.38%)、无创机械通气1例(0.28%)、有创机械通气1例(0.28%)。

研究设计与关键结果

  • 前瞻性单中心观察研究纳入362例奥密克戎感染患者,加强针组136例(37.57%)、常规疫苗组190例(52.49%)、未接种组36例(9.94%)。
  • 171例(47.24%)呈家庭聚集性,涉及69个家庭;74例(20.44%)有一种或多种基础疾病,主要为高血压64例(17.68%)、糖尿病23例(6.35%)、冠心病18例(4.97%)。
  • 215例(59.39%)有一种或多种不适症状,主要为咳嗽158例(43.65%)、咽部不适154例(42.54%)、发热136例(37.57%)。
  • 诊断分型为轻型194例(53.59%)、普通型165例(45.58%)、重型3例(0.83%);入院时新冠病毒IgG抗体滴度为23.17(3.08, 60.77)。
  • 362例均出院,无死亡,其中12例(3.31%)入住ICU;中位病程13(10,15)天,中位住院时间13(11,15)天,中位核酸转阴时间13(10,15)天。
  • 加强针组、常规疫苗组、未接种组IgG抗体滴度分别为41.49(20.32, 81.38)、19.94(2.33, 49.25)、0.16(0.07, 1.94),加强针组和常规疫苗组高于未接种组,加强针组又高于常规疫苗组(均 P < 0.05)。
  • 未接种组重症比例5.56%(2/36)高于常规疫苗组0.53%(1/190)和加强针组0(1/136),核酸转阴时间15(11,16)天、病程15(11,16)天长于常规疫苗组的12(10,15)天和加强针组的13(11,15)天,ICU入住比例16.67%(6/36)高于常规疫苗组2.63%(5/190)和加强针组0.74%(1/136),三组间差异均有统计学意义(均 P < 0.05)。

证据类型、等级与局限

  • 证据类型:前瞻性单中心观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为奥密克戎变异株传染性极强、聚集性发病但临床症状轻,疫苗尤其加强针在预防奥密克戎感染患者向重症进展和改善预后方面仍然有效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the epidemiological and clinical characteristics of patients infected by novel coronavirus Omicron variant, and also to analyze whether vaccination against novel coronavirus has an impact on the severity and prognosis of Omicron patients.

METHODS: A prospective, single-center observational study was conducted to collect data of consecutive patients with Omicron variant infection admitted to the designated hospital for coronavirus disease 2019 (COVID-19) charged by Tianjin COVID-19 rescue medical team of Tianjin Third Central Hospital, from January 8 to February 2, 2022. The clinical characteristics of the patients were analyzed, and the influence of whether the patients were inoculated with booster vaccination on the condition and outcome was analyzed. Data were collected including epidemiological, clinical features, laboratory and imaging examination, treatment measures and clinical outcomes, and difference between groups was analyzed.

RESULTS: A total of 362 patients were included, including 136 cases (37.57%) in the booster group, 190 cases (52.49%) in the routine vaccination group, and 36 cases (9.94%) in the unvaccinated group. There was a trend of concentrated distribution of patients, of which 171 cases (47.24%) patients showed family clustering, involving 69 families. Seventy-four cases (20.44%) of the 362 patients had one or more underlying diseases, mainly hypertension (64 cases, 17.68%), diabetes mellitus (23 cases, 6.35%), and coronary heart disease (18 cases, 4.97%); 215 patients (59.39%) had one or more discomfort symptoms, mainly cough (158 cases, 43.65%), pharyngeal discomfort (154 cases, 42.54%) and fever (136 cases, 37.57%). The diagnostic typing was mild type in 194 cases (53.59%), moderate type in 165 cases (45.58%) and severe type in 3 cases (0.83%). The patients had elevated immunoglobulin G (IgG) antibody titers to the novel coronavirus on admission [23.17 (3.08, 60.77)]. Patients were medically isolated and the main treatment measures included traditional Chinese medicine identification (Chinese medicine or tonics) in 265 cases (73.20%), prone treatment in 188 cases (51.93%), anticoagulation with low-molecular heparin in 106 cases (29.28%), immunomodulatory therapy with thymofacine in 21 cases (5.80%), antimicrobial drugs in 20 cases (5.52%), transnasal high-flow oxygen therapy in 12 cases (3.31%), glucocorticoids in 5 cases (1.38%), non-invasive mechanical ventilation in 1 case (0.28%), and invasive mechanical ventilation in 1 case (0.28%). A total of 362 patients were discharged with no deaths, of which 12 patients (3.31%) were admitted to the intensive care unit (ICU). The median duration of illness was 13 (10, 15) days, the median length of hospitalization was 13 (11, 15) days, and the median time to nucleic acid conversion was 13 (10, 15) days. Compared with the unvaccinated group, the IgG antibody titers of patients in the booster and routine vaccination groups [41.49 (20.32, 81.38), 19.94 (2.33, 49.25) vs. 0.16 (0.07, 1.94)] and the proportion of mild patients [66.91% (91/136), 48.94% (93/190) vs. 27.28% (10/36)] were higher, which were also higher in the booster vaccination group than in the conventional vaccination group (all P < 0.05). Compared to the conventional and booster vaccination groups, the unvaccinated group had a higher proportion of severe patients [5.56% (2/36) vs. 0.53% (1/190), 0 (1/136)], longer time to nucleic acid conversion [days: 15 (11, 16) vs.12 (10, 15), 13 (11, 15)], and longer disease duration [days: 15 (11, 16) vs. 12 (10, 15), 13 (11, 15)], and a higher percentage of ICU admissions [16.67% (6/36) vs. 2.63% (5/190), 0.74% (1/136)], with statistically significant differences among the three groups (all P < 0.05).

CONCLUSIONS: Omicron variant is extremely infectious with aggregated onset, but its clinical symptoms are mild. The vaccine, especially the booster vaccination, remains effective in preventing severe-stage progression and improving prognosis in patients with Omicron variant infection.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Feng Q, Wang Z, Yu H, et al. [Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35728844. doi:10.3760/cma.j.cn121430-20220223-00167

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。